Sajad Nourollahi; Freshteh Hashemi; Elham Shafiei; Omid Pirinegad
Abstract
Background: Research evidence has approved the effectiveness of surfactant prescription for respiratory distress syndrome (RDS). However, previous studies have not reported the priority ...
Read More
Background: Research evidence has approved the effectiveness of surfactant prescription for respiratory distress syndrome (RDS). However, previous studies have not reported the priority of curosurf and Beraksurf. The present study aimed to compare the effectiveness of Iranian surfactant (beraksurf) and Italian surfactant (curosurf) in the treatment of pulmonary distress.Methods: This clinical trial was performed on 80 premature infants with respiratory distress in NICU of Taleghani Hospital in Ilam, all of whom were treated with surfactant.Results: There was no significant difference regarding the duration of needs for ventilation and/or oxygen, duration of hospitalization, pulmonary hemorrhage, bronchopulmonary dysplasia, intraventricular hemorrhage, patent ductus arteriosus (PDA) and pneumothorax between the groups (p>0.05).Conclusion: Beraksurf seems to be as effective as curosurf in premature neonates with RDS, but is less expensive than it.
